BACK TO THE BOUTIQUE INVESTOR BLOG

A Bitter Pill: Why Big Pharmas Era of Big Profits May Be Expiring


Pharmaceutical companies, pressured by buyers to lower drug prices, find their high profit margins threatened.

Click to Read Post

WRITTEN BY

PUBLISHED: August 8, 2019

Get Our Latest Posts Delivered Right To Your Inbox.

Please enter a valid email address

More Like This


A Prescription for Growth? Why Pharma Companies Are Testing New Tactics to Refill Their Drug Pipelines

 
Many pharmaceutical companies are shifting away from large acquisitions, instead opting to buy smaller firms with riskier, earlier-stage drug candidates. Others are experimenting with new strategies altogether.
Read Blog

Why Subscription Revenue is Lifting the Enterprise Software Industry and Investor Expectations

 
Selling software as a service instead of a product has been a boon for enterprise software companies. But will their growth translate to high profits?
Read Blog

Faster Fashion: Why Being Quick to Market Matters More Now for Apparel Companies

 
To regain market share lost to nimble competitors, established footwear and apparel brands are taking steps to accelerate design, production, and sales.
Read Blog

Thanks For Subscribing

You will receive investing know-how at .

  Back To Top